Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revive acquires Natural Dentist

This article was originally published in The Tan Sheet

Executive Summary

Revive Personal Products Co. looks to invest "heavily" in promoting The Natural Dentist products to dental professionals with the closing its acquisition of the natural-positioned oral-care brand. Medford, Mass.-based Natural Dentist's line consists of four toothpastes - Original, Healthy Teeth & Gums Whitening Plus, Fluoride Free and Sparkle Berry Blast for Kids - and six rinses, including Antigingivitis, Antiseptic, Healthy Gums, Pre-Brush Whitening, Healthy Teeth Anticavity Fluoride and Cavity Zapper Fluoride. The products contain natural peppermint and sage oils to prevent and reduce plaque, antiseptic ingredients such as menthol and xylitol and silica to whiten teeth. The brand is sold in natural food and drugstore chains including Harris Teeter, Whole Foods, CVS and Rite Aid. Madison, N.J.-based Revive's existing oral-care portfolio includes Stim-U-Dent Plaque Removers and Fresh 'n Brite Denture Cleaning Paste. Revive declined to give financial details on the deal but noted Natural Dentist founder Bill Stern will join the firm

You may also be interested in...



Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.

Topics

UsernamePublicRestriction

Register

PS104024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel